FDA Pre-Sub Readiness Calculator

This calculator helps teams answer one practical question before submitting a Q-Submission request: are we ready to ask high-value FDA questions, or are we still collecting fundamentals? The model converts common Pre-Sub preparation work into a weighted score so teams can prioritize gaps in intended use clarity, evidence maturity, risk framing, and meeting design.

How this readiness model works

The model applies weighted scoring, because FDA meeting outcomes depend heavily on quality of problem framing and the precision of submitted questions. Teams often over-invest in volume and under-invest in decision architecture. A shorter package with well-structured questions usually outperforms a longer package with diffuse questions and mixed language. The weighting reflects that practical reality.

Weights used in this tool are: intended use clarity (20%), pathway rationale (15%), evidence maturity (20%), risk framing (15%), question quality (20%), and cross-functional readiness (10%). Total score is normalized to 100. Scores above 80 generally indicate meeting-ready packages; scores from 60 to 79 usually indicate partially ready submissions with manageable risk; scores below 60 usually indicate high rework probability before FDA interaction.

Why readiness scoring matters for Q-Submission quality

Teams searching terms like "FDA pre-submission meeting checklist", "how to prepare for Q-Submission", and "pre-sub package template" often assume that completeness equals readiness. In practice, readiness is not binary. A package can be complete in format but weak in logic. Readiness scoring protects against this false confidence by forcing explicit judgments across core domains that determine whether FDA feedback will be actionable.

For example, if intended use language drifts across sections, FDA may spend meeting time clarifying scope instead of evaluating your core technical questions. If risk framing is disconnected from your verification strategy, FDA may challenge your assumptions without giving directional feedback on your actual decision points. If your questions are broad or stacked, answers become qualified and harder to operationalize. These are avoidable issues, but only when teams detect them before submission.

A robust readiness process should also improve internal alignment. Regulatory, clinical, quality, engineering, and commercial functions should interpret intended use and success criteria the same way. Misalignment can remain hidden until final review week, where correction cost is highest. The calculator highlights weak domains early so you can set targeted workstreams with clear ownership.

Score interpretation and action plan

80-100: meeting-ready with focused refinements

If your score is in this range, you are likely ready to proceed with final editorial controls, dry-run prep, and submission QA. Focus on tightening question phrasing, ensuring traceability from evidence to claims, and rehearsing concise responses for predictable challenge topics. At this stage, incremental quality gains come from precision and consistency, not broad rewrites.

60-79: conditionally ready

This range is common for growing teams. You may proceed if critical low-scoring domains are addressed first. Prioritize intended use lock, question architecture redesign, and explicit risk-evidence crosswalks. Keep iteration cycles short. Avoid adding large new sections unless required; improve decision clarity inside existing structure.

Below 60: high-rework risk

This score usually indicates structural gaps that can reduce the value of FDA interaction. Slow down and remediate fundamentals: scope definition, evidence map, risk logic, and ownership model. A rushed submission from this baseline often produces ambiguous feedback and larger downstream rework.

EEAT: practical operator guidance from repeated delivery patterns

Across repeated medical device submission projects, the strongest predictor of a useful Pre-Sub meeting is not page count, but question discipline. Effective teams present decision-oriented questions that are specific, bounded, and tied to explicit data assumptions. They distinguish what is already decided from what FDA input is needed to decide. They avoid rhetorical questions and avoid asking FDA to co-author strategy.

Another repeated pattern is over-claiming maturity. Teams sometimes label evidence "sufficient" without documenting failure modes, edge conditions, or unresolved confounders. FDA reviewers often respond by broadening requests or withholding directional guidance. A better approach is transparent maturity framing: what is known, what is uncertain, and what decision the current evidence can support.

High-performing teams also maintain linguistic control. Intended use phrasing, risk statements, and validation endpoints are synchronized across sections and slides. This reduces interpretation drift and improves reviewer confidence. Linguistic drift is one of the most common hidden failure modes in multidisciplinary authoring environments.

Finally, teams that run realistic internal simulations perform better. Dry-runs should include role discipline, interruption handling, and concise escalation logic. The goal is not presentation polish; it is decision communication under pressure. This is especially important when multiple experts share the call.

Connection to provider selection

Use this readiness score before evaluating external support. Providers are most useful when scoped against real gaps, not generic uncertainty. If your score is low in question architecture and risk framing, choose firms that demonstrate strength in those exact domains. If your score is low in operations and velocity, choose execution-heavy teams with visible weekly delivery rhythm. This prevents expensive mismatch and improves proposal quality.

To compare options, return to Compare +50 FDA Q-Submission Providers and shortlist by domain fit, not brand familiarity.

Citations

• FDA: Requests for Feedback and Meetings for Medical Device Submissions (Q-Submission Program)
• FDA: Premarket Notification (510(k))
• 21 CFR Part 807 Subpart E
• FDA: Software submission content guidance context

Implementation playbook for teams scoring below target

If your score is below target, convert the output into a seven-day remediation sprint. Day one should lock scope and decision owners. Day two and three should close intended use language drift by consolidating wording into one controlled statement used everywhere. Day four should rebuild question architecture so each question maps to one explicit decision. Day five should run cross-functional challenge review to test whether evidence and risk logic support each question. Day six should apply editorial and traceability QA. Day seven should run a simulated meeting with time-boxed responses and escalation rules.

This sprint pattern is effective because it transforms abstract readiness concerns into bounded execution. It also exposes hidden dependencies early, such as missing test summaries, unresolved claim wording, or conflicting clinical assumptions. Teams that run these short cycles usually improve score reliability and reduce final-week churn.

For quality control, use a simple three-column evidence matrix: claim, supporting data, known limitation. If a claim has no mapped data, reduce the claim or add a data plan. If a limitation is large, surface it transparently and ask FDA a bounded question. This approach improves trust and improves the probability of useful directional feedback.

Readiness metrics that should be tracked weekly

Track at least five metrics: percentage of stabilized intended use statements, percentage of questions with explicit decision target, percentage of risks with mapped controls, percentage of package sections with owner sign-off, and number of unresolved cross-functional conflicts older than 48 hours. These metrics are lightweight, but they predict whether readiness is actually improving.

Do not over-index on page count or draft volume. More pages can hide low decision quality. Strong teams optimize for clarity, traceability, and closure rate on critical gaps. If your closure rate slows for two weeks, trigger leadership review and reset priorities. This avoids quiet schedule erosion that often appears only near submission deadline.

As a final check, require every major section owner to answer one question: \"What decision does this section enable?\" If the answer is unclear, the section likely needs redesign. This single prompt is a practical quality filter for late-stage readiness reviews.

Related resources

FDA Pre-Sub Timeline Calculator helps estimate realistic cycle time by novelty, test readiness, and revision loops. FDA Pre-Sub Budget Calculator converts team capacity and provider scope into cost scenarios. For broader submission planning, see 510(k) checklist and 510(k) fees and timeline guide.